Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: Comparison with the Memorial Sloan-Kettering prognostic factors model

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Bamias, Aristotelis ^a   Karadimou, Alexandra ^a   Lampaki, Sofia ^b   Lainakis, George ^a   Malettou, Lia ^c   Timotheadou, Eleni ^b   Papazisis, Kostas ^d   Andreadis, Charalambos ^d   Kontovinis, Loukas ^d   Anastasiou, Ioannis ^a   Stravodimos, Kostas ^a   Xanthakis, Ioannis ^b   Skolarikos, Andreas ^a   Christodoulou, Christos ^e   Syrigos, Kostas ^a   Papandreou, Christos ^f   Razi, Evangelia ^g   Dafni, Urania ^c   Fountzilas, George ^b   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Hellenic Cooperative Oncology Group   (Greece)

^d THEAGENIO CANCER HOSPITAL   (Greece)

^e METROPOLITAN HOSPITAL   (Greece)

^f UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^g HYGEIA HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA2A INTERFERON; CALCIUM; HEMOGLOBIN; LACTATE DEHYDROGENASE; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ACCURACY; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD TOXICITY; CALCIUM BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER SURGERY; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEMORIAL SLOAN KETTERING PROGNOSTIC FACTORS MODEL; MULTIPLE CYCLE TREATMENT; MULTIPLE REGRESSION; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; SEX DIFFERENCE; SURVIVAL RATE; THYROID DISEASE; TREATMENT RESPONSE; VALIDITY; ALGORITHM; KIDNEY TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; ONCOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PROGNOSIS; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77949455569     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-45     Document Type: Article

References (27)

1. Cohen H, McGovern F. Renal Cell Carcinoma. N Engl J Med 2005, 353:3477-3490.
2. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004, 171:1071-1076. 10.1097/01.ju.0000110610.61545.ae, 14767273.
3. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998, 16:2261-2266.
4. Jonasch E, Haluska FG. Interferon in oncological practice: review of Interferon biology, clinical applications, and toxicities. Oncologist 2001, 6:34-55. 10.1634/theoncologist.6-1-34, 11161227.
5. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000, 6:S55-S57.
6. Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, Sevin E, Caty A, Tubiana-Mathieu N, Escudier B, . the French Immunotherapy Intergroup Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J Clin Oncol 2005, 23(16S):4511. the French Immunotherapy Intergroup.
7. Johannsen M, Brinkmann OA, Bergmann L, Heinzer H, Steiner T, Ringsdorf M, Romer A, Roigas J. The role of cytokine therapy in metastatic renal cell cancer. Eur Urol Supplements 2007, 6:658-664.
8. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-40.
9. Motzer RJ, Murphy BA, Bacik J, Russa P, Mazudmar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2001, 20:289-96.
10. Mekhail TM, Abou-Jawde RM, BouMerhi G, Malhi S, Wood L, Elson P, Bukowski R. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005, 23:832-41. 10.1200/JCO.2005.05.179, 15681528.
11. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124. 10.1056/NEJMoa065044, 17215529.
12. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan MH, Simantov R, Bukowski RM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134. 10.1056/NEJMoa060655, 17215530.
13. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N. Bevacizumab plus interferon alfa-2a for the treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:22-29.
14. Chow LQM, Eckhardt SG. Sunitinib: From rational design to clinical efficacy. J Clin Oncol 2007, 25:884-896. 10.1200/JCO.2006.06.3602, 17327610.
15. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, DePrimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E. Safety, pharmacokinetic, and antitumor activity of SU1 a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 1248, 24:25-35.
16. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI. Toxicities associated with the administration of Sorafenib, Sunitinib, and Temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008, 53:917-930. 10.1016/j.eururo.2007.11.037, 18054825.
17. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating curves: A nonparametric approach. Biometrics 1988, 44:837-845. 10.2307/2531595, 3203132.
18. Choueri TK, Vaziri SA, Rini BI, Elson P, Bhalla I, Jaeger E, Weinberg V, Waldman FM, Zhou M, Bulowski RM, Ganapathi R. Use of von Hippel-Lindau (VHL) mutation to predict objective response to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (RCC). J Clin Oncol 2007, 25(18S):238.
19. Patel PH, Chadalavada RS, Ishill NM, Patil S, Reuter VE, Motzer RJ. Hypoxia-inducible factor (HIF) 1a and 2a levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinomas (RCC). J Clin Oncol 2008, 26(15S):252.
20. Hutson TE, Davis ID, Machiels JH, de Souza PL, Baker K, Bordogna W, Westlund R, Crofts T, Pandite L, Figlin RA. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008, 26(15S):261.
21. Szczylik C, Porta C, Bracarda S, Hawkins R, Bjarnason G, Oudard S, Carteni G, Hariharan S, Gore M. Sunitinib in patients with or without prior nephrectomy in an expanded access trial of metastatic renal cell carcinoma. J Clin Oncol 2008, 26(15S):280.
22. Sternberg CN, Porta C, Bracarda S, Carteni G, Lo Re G, uggeri EM, Conte P, Monfardini S, Gasparini G, Ciuffreda L. Expanded-access program (EAP) of Sunitinib in 458 patients with metastatic renal cell carcinoma. Ann Oncol 2008, 19(Suppl 8):194.
23. Figlin RA, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Negrier S, Huang X, Kim ST, Chen I, Motzer RJ. Overall survival with sunitinib versus interferon (IFN-alfa as first-line treatment of metastatic renal cell carcinomas (mRCC). J Clin Oncol 2008, 26(15S):256.
24. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Berijamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrintestinal stromal tumors treated at a single institution with Imatinib Mesylate; proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-59. 10.1200/JCO.2006.07.3049, 17470865.
25. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456. 10.1016/S0140-6736(08)61039-9, 18653228.
26. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl J Med 2007, 356:125-34. 10.1056/NEJMoa066838, 17215530.
27. Patil S, Figlin RA, Hutson TE, Michaelson MD, Nigrier S, Kim ST, Huang X, Motzer RJ. Prognostic factors for overall survival with Sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27(15s). abstract 5042.